Loading articles...
Ebola Pandemic Risk in 2026: A Low Probability Assessment
An Ebola pandemic in 2026 is considered unlikely due to established public health responses, vaccine availability, and improved surveillance.
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
ATS 2026 highlights advancements in nontuberculous mycobacteria (NTM) lung disease, focusing on improved detection, optimized therapy, and patient quality of life.
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
BRINSUPRI® receives first approval for non-cystic fibrosis bronchiectasis (NCFB), addressing a significant unmet need in chronic respiratory care.
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
ATS 2026 highlighted epithelial cytokine pathways as a common link in severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and COPD.
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
New real-world evidence presented at ATS 2026 indicates that initiating triple therapy earlier in asthma management may improve patient outcomes.
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
YUTREPIA® (treprostinil) inhalation powder offers a new prostacyclin treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
New insights from ATS 2026 reveal significant discrepancies between patient experiences and pulmonologist perceptions in IPF and PPF management.
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Alpha-1 antitrypsin (AAT) protein extends its protective role beyond established AAT deficiency, influencing general lung health.
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ATS 2026 highlights epithelial dysfunction as a central mechanism in upper and lower airway inflammation, informing evolving management strategies.